and I afternoon. morning include Orlando, Conference These Society month from Annual in highlight website abstracts next be Sandy, This Florida afternoon. this will data Hematology posted like their at you, their the of and A would to perspective Thank gene I hemophilia some also vivo like SB-XXX therapy abstract gene-edited posters the shown would and beta on on ex those American and data. several good our our therapy context that as more posters clinical what for provide in should our to program now you expect on ST-XXX see program cell to thalassemia.
to The that rules, Please this note, to time embargo able were at the submitted due be discuss the this shown of August. data will morning. not published that in abstracts early beyond in were abstracts the we what scope ASH was the
open ASH with candidate, severe which poster First, adult follow-up from SB-XXX, patient to dose-ranging ALTA at study A. patients will data study, gene is partnered contain label, in A discuss like Pfizer. hemophilia the with Phase updated hemophilia I'd therapy our I/II The a
follow-up at levels, high Factor follow-up XX our XXXX updated we from weeks. July You and four data the been subjects have will five, last will VIII from we ranging to data all for the for recall in usage XXX, [indiscernible] showed including patients that was had four data At with XX ISTH first where at bleeding dose analysis approximately dose, and factor ASH rates months. high followed
the low believe events far product abstract that exogenous benefit cessation the presented the and ASH, at replacements the the potential gene deliver the in data a bleeding responses We of to with therapy patients. as have may published well as the hemophilia that elimination - rapid together of to suggest A was and observed we differentiated significant intra of cohort factor thus that continue presented variability kinetics, durability including relatively to
three As X treated experience no transient elevations corticosteroids. submission activity ALT August these Grade levels least with experienced with eight patients at Xrd, events of adverse the the for in and date, of who new were followed highest-dose None five mild loss Factor a of and weeks patients patients the ASH VIII and reported. cohorts, series abstract treated were of were
in at the ALTA a look most study reminder, poster the steroids. were As presentation. forward data prophylactic up-to-date patients showing treated to We ASH with the not
delivery of dependent GATA of binding Moving in on In while transfusion ST-XXX the preclinical with with thalassemia. an beta is editing editing production is fetal In autologous finger cells, also finger the for technology. ex-vivo in patient's the stem zinc patients nuclease to the patient's therapy being Phase hematopoiesis. studies, study, that now hemoglobin disruption healthy gene-edited BCLXXA, I/II hematopoietic allowing nuclease beta therapy candidate of - thalassemia. enhancer erythroid evaluated genes mediated with cell non-viral multi-lineage increased specific endogenous involves cell using ST-XXX erythroid cells own product genes ST-XXX, own zinc our region
specific then patient infused As to the the conditioning shown harvested patient, the on out BCLXXA from and erythroid knock slide busulfan. XX edited back for enhancer, myeloablative deck, of the ST-XXX corporate with the following cells [ph] into
varies zero-beta thalassemia. most of disease from various mutations zero. presentation endogenous on depending from but widely the the severe and The to the can of their are indistinguishable zero-beta form even Beta clinically to and disease, production look potential XX, of beta anemia phenotype patients have patients, patients the slide you lead If other you at disease see is mild these zero patients form the examples beta zero-beta in may modifiers. clinical virtually varies genotype no a of of severe beta-globin where zero that beta
It's our red typical of few enrollment patient. provided for is dependent transfusion notable potentially that significantly allow as beta eight four of transfusions transfusion the competitive study for a that patients prior cell a disease per editing each any as years. enough study severe have they least at technology two severe CRISPR/CasX year blood reminder, enrollment with with required genotype of using less criteria events allows thalassemia packed patients are adult As to a
zero posted Abstract with genotype this zero ASH have phenotypes first equivalent zero-beta The beta the beta to are zero-beta that severe either three or a patients disease morning functionally patients. shows enrolled
DNA patient subsequently the This fetal beta elevated peripheral required increasing last of the indels, and cells has demonstrated the remained genotype. patient After intermittent packed red zero prompt first on-target present in for six infusion. six The a has with levels hemoglobin from cell at time were transfusions hemoglobin. post months patient reconstitution being fetal BCLXXA blood hematopoietic At freed mononuclear follow-up, zero-beta transfusions. blood weeks,
experienced patient genotype levels infusion prompt hematopoietic patient complete zero-beta absence observed a a and rising zero circulating a time endogenous last blood in to is production. has two XX but near of non-beta detected the is Patient indels hemoglobin severe white through This fetal following days of infusion. on-target reconstitution cells the whether with follow-up post hemoglobin there at
the was have AEs in myeloablation. and the Patients that other related recently those in is with the for patient is production a absence one cryoprotectant, received three, who which patient consistent have ST-XXX following severe infusion SAEs end expected SAE been allergic to previously but of the zero-beta has non-beta is resolved no patients reported August. of DMSO, near Besides genotype it complete in infusion, reported where hemoglobin by reaction been there the other endogenous ST-XXX to zero most reported treated all and the product
observed been No has clonal date. hematopoiesis to
to a as to system ASH been is reminder, studies forward cells that this we this more the that Accordingly, the have look first other reboot the to required to ST-XXX and end for of conditioning time in passed only and next for very myeloablative to limited stages. impacts potential at the study. used population is patients this will conditioning XX is towards in burden. in stem sufficient Myeloablative patients very months effect to time As once reflecting show results of even much patient follow-up a marrow there mature this be three early is will such dosed of the month potentially hematopoietic We study in transfusion fully take full data dosed understand shown up drive; how and XXXX the the is study its our the all or of still and allow it preliminary, to manifest have may sufficient longer. re-populate from
call and the Cockroft, CMO, turn now Operations Development Bettina I'll our new over Clinical Update. to for
